Education
About Us
Working with TipRanks
Follow Us
Gyre Therapeutics (GYRE)
NASDAQ:GYRE
GYRE Stock Chart & Stats
$6.81
-$0.21(-2.15%)
At close: 4:00 PM EST
$6.81
-$0.21(-2.15%)
Day’s Range― - ―
52-Week Range$6.11 - $13.75
Previous CloseN/A
Volume104.17K
Average Volume (3M)102.52K
Market Cap
$746.21M
Enterprise Value$713.34M
Total Cash (Recent Filing)$40.40M
Total Debt (Recent Filing)$1.17M
Price to Earnings (P/E)221.0
Beta1.97
Next Earnings
Mar 31, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding90,890,380
10 Day Avg. Volume112,833
30 Day Avg. Volume102,519
Financial Highlights & Ratios
PEG Ratio-0.78
Price to Book (P/B)16.26
Price to Sales (P/S)9.74
P/FCF Ratio-152.11
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue6.65
Enterprise Value/Gross Profit6.97
Enterprise Value/Ebitda47.45
Forecast
1Y Price Target
$19.00Price Target Upside179.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross And Net MarginsSustained exceptionally high gross and strong net margins indicate durable pricing power and low direct costs, enabling reinvestment into R&D or commercialization. These margins provide a buffer against revenue volatility and support long-term profitability if revenue stabilizes.
Extremely Low Leverage And High ROEMinimal leverage gives the company financial flexibility to fund development or weather downturns without heavy interest burdens. The high ROE reflects efficient use of equity to generate profits, a structural strength that supports long-term capital allocation and shareholder value creation.
Regulatory Progress Toward China Approval For HydronidoneOfficial CDE alignment and eligibility for conditional approval/priority review materially shortens regulatory path in a large addressable China market. This structural development can accelerate commercialization, broaden footprint, and de-risk revenue timing if confirmed.
Bears Say
Very Weak Cash GenerationSeverely negative free cash flow growth and minimal operating cash conversion of reported earnings undermine the sustainability of operations and R&D funding. Over months this increases reliance on external financing, dilutes optionality, and raises execution risk for development programs.
Inconsistent / Negative Revenue GrowthLarge recent revenue contraction signals top-line volatility that can erode the durability of margins and complicate scaling commercialization. Persistent or variable revenue trends hinder long-term planning, strain cash flow, and increase dependence on milestone or partner funding.
Concentration Risk On Hydronidone And China PathMaterial dependence on a single asset and a China-focused regulatory pathway concentrates commercial success risk. If regulatory setbacks or trial requirements change, the company's near-term growth and revenue prospects could be disproportionately impacted, limiting diversification.
Gyre Therapeutics News
GYRE FAQ
What was Gyre Therapeutics’s price range in the past 12 months?
Gyre Therapeutics lowest stock price was $6.11 and its highest was $13.75 in the past 12 months.
What is Gyre Therapeutics’s market cap?
Gyre Therapeutics’s market cap is $746.21M.
When is Gyre Therapeutics’s upcoming earnings report date?
Gyre Therapeutics’s upcoming earnings report date is Mar 31, 2026 which is in 36 days.
How were Gyre Therapeutics’s earnings last quarter?
Gyre Therapeutics released its earnings results on Nov 07, 2025. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.047 by -$0.017.
Is Gyre Therapeutics overvalued?
According to Wall Street analysts Gyre Therapeutics’s price is currently Undervalued.
Does Gyre Therapeutics pay dividends?
Gyre Therapeutics pays a Quarterly dividend of $3.6 which represents an annual dividend yield of N/A. See more information on Gyre Therapeutics dividends here
What is Gyre Therapeutics’s EPS estimate?
Gyre Therapeutics’s EPS estimate is 0.06.
How many shares outstanding does Gyre Therapeutics have?
Gyre Therapeutics has 90,890,380 shares outstanding.
What happened to Gyre Therapeutics’s price movement after its last earnings report?
Gyre Therapeutics reported an EPS of $0.03 in its last earnings report, missing expectations of $0.047. Following the earnings report the stock price went down -1.771%.
Which hedge fund is a major shareholder of Gyre Therapeutics?
Currently, no hedge funds are holding shares in GYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gyre Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.79%
12-Months-Change
Fundamentals
Return on Equity
8.06%
Trailing 12-Months
Asset Growth
26.23%
Trailing 12-Months
Company Description
Gyre Therapeutics
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
GYRE Stock 12 Month Forecast
Average Price Target
$19.00
▲(179.00% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Terns Pharmaceuticals
―
Day One Biopharmaceuticals
―
Tyra Bioscience
―
MBX Biosciences, Inc.
―
Ownership Overview
3.87% Insiders
1.55% Mutual Funds
<0.01% Other Institutional Investors
92.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---